Cyclic AMP Binding Proteins in Human Breast Cancer
Author Information
Author(s): W.R. Miller, R.O. Senbanjo, J. Telford, D.M.A. Watson
Primary Institution: University Department of Clinical Surgery, Royal Infirmary, Edinburgh
Hypothesis
The study aims to measure cyclic AMP binding proteins in human breast cancer cytosols and assess their characteristics.
Conclusion
All breast cancer tumours tested showed cyclic AMP binding activity, with levels varying significantly between individual tumours.
Supporting Evidence
- All 100 breast cancer tumours showed cyclic AMP binding activity.
- Binding levels varied from 0.8 to 15 pmol mg-1 cytosol protein.
- The mean dissociation constant was 1.73 x 10-8 M.
- Intra-assay variation was between 4.5 and 7.9%, while inter-assay variation was between 2.1 and 4.0%.
- Similar intra-tumour variations have been reported for other binding proteins.
Takeaway
The study found that all breast cancer samples had proteins that bind cyclic AMP, but the amount varied a lot from one tumour to another.
Methodology
The study involved measuring cyclic AMP binding proteins in cytosols from breast cancer tumours using a specific assay method.
Limitations
The study does not determine the factors influencing cyclic AMP binding protein levels or their relationship to prognosis.
Participant Demographics
Patients with histologically proven breast cancer, T stage 1 to 4.
Want to read the original?
Access the complete publication on the publisher's website